Opinion|Videos|September 30, 2024
Educational Initiatives to Enhance Guideline Adherence in CRM
Key Takeaways
- Targeted education, including workshops and webinars, can enhance provider awareness of evidence-based guidelines for CRM conditions.
- Emphasizing the importance of annual uACR and eGFR testing can improve CKD screening and early detection.
Key opinion leaders explore educational initiatives aimed at enhancing guideline adherence in cardiometabolic risk management, emphasizing effective tactics for improving health outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What educational initiatives can be implemented to improve healthcare provider awareness and adherence to evidence-based guidelines in patients with CRM conditions?
- For example, how could targeted education improve annual testing for uACR and eGFR to screen for CKD?
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
Advertisement
Related to this article
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.
AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.
The conference session featured updates on several clinical trials, including the BRUNELLO trial, for treatment of diabetic macular edema (DME).
Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.
A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
Advertisement
Advertisement
Trending on AJMC
1
CMS Rule Ends Medicaid, CHIP Funding for Pediatric Gender Care
2
Oral JAK Inhibitors Boost Hair Regrowth Odds in Alopecia Areata
3
Medicare Drug Price Negotiations Yield Uneven Out-of-Pocket Savings
4
Panel Calls for Earlier Detection, Clearer Pathways in Rare Glomerular Disease
5